Alcon acquires Neurotech for $550 million
Bitget2026/10/20 20:36- Alcon acquired Neurotech Pharmaceuticals for $550 million, expanding its retina portfolio with ENCELTO.
- Additional contingent payments may be required, including upon achievement of commercial milestones.
- ENCELTO is the only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2, a progressive retinal disease.
- The therapy received FDA approval in March 2025 and is available only in the U.S.
- The transaction is expected to modestly boost net sales growth, slightly dilute core diluted EPS in 2027 and be accretive thereafter.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nomura: Bond short squeeze and AI selloff trigger cross-asset 'reverse dispersion' rotation, with capital flowing into value stocks and small-cap stocks
Nomura Securities analyst McElligott believes that bond tightening and turmoil in the field of artificial intelligence will lead to a market reversal.
AI Is Splitting Software Into Winners and Losers, Citi’s Tyler Radke Says
KOSPI Jumps 3.54%, Nikkei Gains 1.43%, But How Is Oil Driving the Rebound?
Wedbush Bullish on AMD (AMD.US) Before Earnings: Server CPUs Take the Lead, 2027 Guidance Awaits Validation
AMD will announce its Q3 FY2026 results on November 3. Wedbush analyst Matt Bryson stated in the latest outlook that the actual figures for this quarter may not be the biggest variable; rather, the strength of server CPU sales will determine the short-term upside potential.
Crypto prices
More
